HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells

Immunological Investigations

Volumn 41, Issue 8, 2012, Pages 831-846

  MacHino, Takayuki ^a   Okoshi, Yasushi ^a   Miyake, Yasuyuki ^a   Akatsuka, Yoshiki ^b   Chiba, Shigeru ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADCC; Allogeneic; HLA C; NK cells; Rituximab

Indexed keywords

HLA ANTIGEN CLASS 1; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CONTROLLED STUDY; DONOR; GENE SILENCING; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HISTOCOMPATIBILITY; HLA-C ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; ISOANTIGENS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOMA; RECEPTOR CROSS-TALK; RECEPTORS, KIR; RNA, SMALL INTERFERING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870939008     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.691148     Document Type: Article

References (19)

1. Akatsuka, Y., Goldberg, T.A., Kondo, E., Martin, E.G., Obata, Y., Morishima, Y., Takahashi, T., Hansen, J.A. (2002). Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 59:502-511.
2. Baron, F., Petersdorf, E.W., Gooley, T., Sandmaier, B.M., Malkki, M., Chauncey, T.R., Maloney, D.G., Storb, R. (2009). What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol. Blood Marrow Transplant 15:580-588.
3. Boyington, J.C., Sun, P.D. (2002). A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol. Immunol. 38:1007-1021.
4. Cartron, G., Watier, H., Golay, J., Solal-Celigny, P. (2004). From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635-2642.
5. Farag, S.S., Fehniger, T.A., Ruggeri, L., Velardi, A., Caligiuri, M.A. (2002). Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100:1935-1947.
6. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., Maccario, R., Bonetti, F., Wojnar, J., Martinetti, M., et al. (2003). Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814-819.
7. Gumperz, J.E., Litwin, V., Phillips, J.H., Lanier, L.L., Parham, P. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181:1133-1144.
8. Hatjiharissi, E., Xu, L., Santos, D.D., Hunter, Z.R., Ciccarelli, B.T., Verselis, S., Modica, M., Cao, Y., Manning, R.J., Leleu, X., et al. (2007). Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110:2561-2564.
9. Hoglund, P., Brodin, P. Current perspectives of natural killer cell education by MHC class I molecules. Nat. Rev. Immunol. 10:724-734.
10. Kim, S., Poursine-Laurent, J., Truscott, S.M., Lybarger, L., Song, Y.J., Yang, L., French, A.R., Sunwoo, J.B., Lemieux, S., Hansen, T.H., et al. (2005). Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709-713.
11. Koene, H.R., Kleijer, M., Algra, J., Roos, D., E.G. Kr. von dem Borne, A., and de Haas, M. (1997). Fcgamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fcgamma RIIIa, independently of the Fcgamma RIIIa-48L/R/H phenotype. Blood 90:1109-1114.
12. Kroesen, B.J., Mesander, G., ter Haar, J.G., The, T.H., and de Leij, L. (1992). Direct visualisation and quantification of cellular cytotoxicity using two colour floures-cence. J. Immunol. Meth. 156:47-54.
13. Lanier, L.L. (1998). NK cell receptors. Annu. Rev. Immunol. 16:359-393.
14. Matin, M.M., Walsh, J.R., Gokhale, P.J., Draper, J.S., Bahrami, A.R., Morton, I., Moore, H.D., Andrews, P.W. (2004). Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. Stem Cells 22:659-668.
15. Parham, P., McQueen, K.L. (2003). Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat. Rev. Immunol. 3:108-122.
16. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N., Anderson, D.R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
17. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R.S., Martelli, M.F., Velardi, A. (1999). Role of natural killer cell alloreactiv-ity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333-339.
18. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
19. Stein, M.N., Shin, J., Gudzowaty, O., Bernstein, A.M., and Liu, J.M. (2006). Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res. 26:1759-1763.